drugset / Trial / NCT00211198
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Phase 4
Completed
60 enrolled
Eisai Inc.
Ligand Pharmaceuticals · collabNational Cancer Institute (NCI) · collabTufts Medical Center · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.
Timeline
- Start
- 2001-05
- Primary completion
- 2005-01
- Completion
- 2006-01
Publications
- Background Francine Foss, Madeleine Duvic, Larisa Geskin, Joseph Anderson, Pierluigi Porcu, Raymond J. Hohl, Maureen Cooper, Jasmine M. Zain, John Zic, Patrica Hibberd, and Mark Acosta Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2712.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denileukin difitox | Unknown | — | — |